STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 3, 1998. STAAR Surgical Company is a Delaware corporation engaged in the development, manufacture, and sale of ophthalmic products, including the Implantable Contact Lens and Glaucoma Wick. The company operates internationally with significant sales in Europe, South Africa, Australia, and Southeast Asia.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $14.10 million | $10.55 million |
| Gross Profit | $9.82 million (69.6% margin) | $8.10 million (76.7% margin) |
| Operating Income | $2.73 million | $2.72 million |
| Net Income | $1.67 million | $1.75 million |
| Cash and Equivalents (End of Period) | $3.59 million | $4.00 million |
| Net Cash from Operating Activities | $4.27 million | $1.36 million |
| Total Debt (Current + Long-term) | $7.60 million | N/A |
| Current Ratio | 2.5:1 | 3.4:1 (Jan 2, 1998) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 33.6% year-over-year, driven by a $4.2 million increase in international sales from newly acquired or formed foreign distributors and growth in new products.
- Margin Compression: Gross margin declined from 76.7% to 69.6%. This was primarily due to the inclusion of distribution business (lower margin) from the new foreign distributor and lower average selling prices for intraocular lenses (IOLs) due to competition.
- Acquisition Impact: On January 5, 1998, the company acquired a 60% interest in a foreign distributor for approximately $4.6 million, recording $4.1 million in goodwill. This acquisition significantly increased accounts payable and inventory levels.
- Expense Trends: Marketing and selling expenses rose to 31.1% of revenue (from 27.2%) due to the new distributor's costs. General and administrative expenses decreased as a percentage of revenue (11.9% vs 14.4%) due to revenue absorption.
- Liquidity: Cash and cash equivalents decreased by $2.7 million during the quarter, primarily due to payments on the line of credit and increased inventory stocking for international rollout.
Outlook, Risks, and Management Commentary
- Outlook: Management expects cost of sales as a percentage of revenue to decline as the new distributors' product mix shifts toward more company-manufactured products. The company anticipates continued profitability and believes future cash needs will be met by operations or additional financing.
- Risks: International operations expose the company to fluctuating exchange rates, foreign government regulations on fund transfers, export/import duties, and political instability. The company recorded a net foreign translation loss of $390,887 for the quarter.
- Unusual Items: Royalty income decreased by $192,000 compared to the prior year. The acquisition of the foreign distributor resulted in a significant one-time increase in goodwill and accounts payable.
Investor Verification Checklist
- Verify the sustainability of the 33.6% revenue growth given the one-time impact of the foreign distributor acquisition.
- Monitor the trend of gross margins as the product mix of the new distributor shifts toward higher-margin manufactured goods.
- Assess the impact of competitive pricing pressures on the core intraocular lens (IOL) business.
- Review the company's ability to manage working capital, specifically the $2.7 million cash decrease and increased inventory levels.
- Confirm the status of the line of credit and the company's reliance on it for liquidity.